The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.
Open accessAbstract
Studies were undertaken to investigate acquired resistance to cisplatin in human ovarian cancer cells. The cell lines A2780 and A2780/CP70 were studied to assess their respective characteristics of drug accumulation and efflux, cytosolic inactivation of drug, and DNA repair. All experiments were performed using 1-h drug exposures. The A2780/CP70 cell line was 13-fold more resistant to cisplatin than A2780 cells. When studied at their respective IC50 doses, drug accumulation rates were similar for the two cell lines. However, the resistant cell line was twofold more efficient at effluxing drug, which was associated with reduced total drug accumulation for equivalent micromolar drug exposures. At equivalent levels of total cellular drug accumulation, the two cell lines formed the same levels of cisplatin-DNA damage, suggesting that cytosolic inactivation of drug does not contribute to the differential in resistance between these cell lines. Resistant cells were also twofold more efficient at repairing cisplatin-DNA lesions in cellular DNA and in transfected plasmid DNA. We conclude that in these paired cell lines, alterations in drug uptake/efflux and in DNA repair are the major contributing factors to acquired resistance to cisplatin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Cloning. A Laboratory Manual
Wood, E. (1983) · Biochemical Education · doi:10.1016/0307-4412(83)90068-7 · Cited by 29,533
Eastman, A. (1987) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(87)90009-x · Cited by 539
Self-citationKnox, R. J., Friedlos, F., Lydall, D. A., & Roberts, J. J. (1986) · PubMed · Cited by 498
Subcellular components: preparation and fractionation;
Birnie, G. D. (1972) · Cited by 422
Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II)
Eastman, A., & Schulte, N. (1988) · Biochemistry · doi:10.1021/bi00413a022 · Cited by 312
Self-citationReed, E., Ozols, R. F., Tarone, R., Yuspa, S. H., & Poirier, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.14.5024 · Cited by 217
Self-citationOne pyrimidine dimer inactivates expression of a transfected gene in xeroderma pigmentosum cells.
Protić-Sabljić, M., & Kraemer, K. H. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.19.6622 · Cited by 186
Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells
Andrews, P., Murphy, M., & Howell, S. (1987) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00254568 · Cited by 176
Effect of Glutathione on DNA Repair in Cisplatin-Resistant Human Ovarian Cancer Cell Lines
Lai, G.-M., Ozols, R. F., Young, R. C., & Hamilton, T. C. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.7.535 · Cited by 167
Enhanced DNA repair and resistance to cisplatin in human ovarian cancer
Lai, G., Ozols, R. F., Smyth, J. F., Young, R. C., & Hamilton, T. C. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90325-5 · Cited by 156
Cited by
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Mechanisms of resistance to cisplatin
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00141-5 · Cited by 869
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
Go, R. S., & Adjei, A. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.409 · Cited by 697
Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair.
Chu, G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42175-2 · Cited by 651
Rixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K., & Fojo, T. (1996) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)81490-6 · Cited by 615
Self-citation
Metadata
- Authors
- Parker, R. J., Eastman, A., Bostick-Bruton, F., & Reed, E.
- Venue
- Journal of Clinical Investigation
- Published
- 1991-03-01
- Volume
- 87
- Issue
- 3
- Pages
- 772-777
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1983426353
- Cited by
- 299
- References
- 18
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. https://app.cochat.ai/papers/10.1172/jci115080
- The paper
- Parker, R. J., Eastman, A., Bostick-Bruton, F., & Reed, E. (1991). Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. Journal of Clinical Investigation. https://doi.org/10.1172/jci115080
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.